Insight Resource Library Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: obesity, diabetes, MASH, CKD, IPF and IBD. Filtered (28) Filters Reset all × 5/6 nephrectomy (Nx) rat × DIO mouse × Renin–angiotensin system × Search × Resource type Data presentation (0) Poster (6) Publication (22) 3D imaging video (0) Webinar (0) Category × Disease model (222) Cardiovascular disease (11) AngII mouse (2) DIO-ApoE-KO mouse (1) DIO-LDLR-KO mouse (4) DIO-PCK9-AAV mouse (1) Isoprenaline-induced cardiomyopathy (1) Cholangiopathy (1) Bile duct ligation (BDL) mouse (1) Mdr2-KO mouse (1) CNS disease (39) Alzheimer's disease models (9) CNS activation (12) Drug distribution (6) Gene expression (1) Gene therapy (1) Parkinson's disease models (6) Diabetes (33) db/db mouse (17) Non-obese diabetic (NOD) mouse (4) ZDF rat (10) Inflammatory bowel disease (3) Acute DSS-IBD mouse (0) Chronic DSS-IBD mouse (3) Idiopathic pulmonary fibrosis (7) BLEO-IPF mouse (4) Chronic BLEO-IPF mouse (2) HFD-BLEO-IPF mouse (0) Kidney disease (33) Acute kidney injury (4) Bilateral ischemia reperfusion injury (bIRI) mouse (1) Unilateral ischemia reperfusion injury (uIRI) mouse (3) Chronic kidney disease (18) Anti-GBM glomerulonephritis mouse (2) Adenine diet-induced (ADI) nephropathy mouse (5) Polycystic kidney disease (PCK) rat (1) Unilateral ureteral obstruction (UUO) mouse (4) 5/6 nephrectomy (Nx) rat (3) Diabetic kidney disease (17) db/db-UNx mouse (1) ReninAAV UNx db/db mouse (11) ZSF-1 rat (0) Knock-out mouse models (8) Metabolic dysfunction-associated steatohepatitis (76) GAN DIO-MASH mouse (30) GAN DIO-MASH-HCC mouse (8) GAN ob/ob-MASH mouse (5) CDAA-HFD mouse (9) CDAA-HFD rat (10) AMLN DIO-MASH mouse (18) AMLN ob/ob-MASH mouse (13) Obesity (51) Bariatric surgery (10) DIO mouse (22) DIO rat (14) ob/ob mouse (8) Therapeutic Area (241) Alzheimer's disease (13) Alcoholic steatohepatitis (2) Cardiovascular disease (10) Chronic kidney disease (28) Cholangiopathy (1) Diabetes (55) Diabetic cardiomyopathy (2) Diabetic kidney disease (18) Hepatocellular carcinoma (6) Idiopathic pulmonary fibrosis (7) Inflammatory bowel disease (3) Metabolic dysfunction-associated steatohepatitis (84) Obesity (80) Parkinson's disease (8) Target (149) Alpha-synuclein (1) Autotaxin (1) Beta amyloid (4) Acetyl-CoA carboxylase (3) Amylin receptor (4) Angiotensin converting enzyme (ACE) (5) AMPK (1) ASBT (2) CB1 receptor (5) CCK receptor (4) D2 receptor (3) DPP-IV (2) Fatty acid synthase (1) FGF receptor-1 (3) FXR (13) GCC receptor (1) GFRAL (1) Ghrelin receptor (3) GIP receptor (4) GLP-1 receptor (73) GLP-2 receptor (5) Glucagon receptor (5) GPR119 (0) GPR120 (1) G-protein coupled receptor 10 (GPR10) (1) HSD17b13 (1) 5-HT2C receptor (3) IL-1beta receptor (1) Insulin receptor (2) mARC1 (1) MC4 receptor (4) Monoamine transporter (2) Leptin receptor (1) Neuropeptide FF receptor type 2 (1) Neurotensin receptor (1) Nicotinic acetylcholine receptor (1) NPY receptor (2) NMU receptor (2) Paraoxonase-2 (1) PCSK9 (1) PICK1 (1) PPAR (23) PSD-95 (1) Renin–angiotensin system (3) Secretin receptor (1) SGLT-2 (5) TAAR1 (1) TGF-beta (7) TGR5 (2) THR-ß receptor (5) Y2 receptor (3) Compound (146) Aducanumab biosimilar (4) Adeno-associated virus (AAV)-mediated gene therapy (1) A3907 (2) Adrenomedullin (2) Alk5 inhibitor (6) ALT-801 (1) Amylin (3) Amylin receptor agonist (1) BLD-0409 (1) Bromocriptine (2) CHS-131 (1) Captopril (1) Cilofexor (1) Cotadutide (1) DA-1241 (1) Dapagliflozin (2) Dietary intervention (4) Exenatide (9) Elafibranor (10) Empagliflozin (4) Exendin-4 analogues (3) FGF21 (3) Firsocostat (3) GDF15 analogues (1) Ghrelin (1) GIP receptor agonist (1) GIPRA (1) GIP receptor antagonist (1) Glibenclamide (1) GLP-1 (5) GLP-1 receptor agonist (5) GLP-2 (1) Glucagon receptor agonist (1) Glucose-dependent insulinotropic polypeptide (GIP) (1) Guanylin (1) GUB06-046 (1) GUB08-248 (1) GUB09-123 (1) GUB09-145 (2) GUB08251 (1) GUB021794 (1) GUBamy (1) GS-834356 (1) HSD17b13 inhibitor (1) HSG4113 (1) Icosabutate (1) ID166 (0) Insulin (1) INT-767 (4) INT-787 (0) Lanifibranor (10) LEAP-2 (2) Leptin (1) Linagliptin (5) Liraglutide (30) Lisinopril (5) Lorcaserin (3) MEDI0382 (1) mPD95 (1) Neuromedin U (2) Neurotensin (1) Neurturin (1) Nicotine (1) Obeticholic acid (11) Oxyntomodulin (1) PYY3-36 (4) Prolactin-releasing peptide (1) Resmetirom (7) Rimonabant (4) Rosiglitazone (2) S961 (1) Salmon calcitonin (1) SEFA-1024 (1) Seladelpar (2) Semaglutide (31) SER140 (1) Setmelanotide (3) Sibutramine (4) TAAR1 agonists (1) Taspoglutide (1) Teduglutide (2) TVB-3664 (1) UCCB01-147 (1) Uroguanylin (1) Vutiglabridin (1) Y2 receptor agonist (1) ZP3022 (3) Method/Endpoint (264) 3D imaging (56) Adeno-associated virus (AAV)-mediated gene delivery (14) Atherosclerotic plaques (3) Beta-cell mass (12) Blood pressure (1) Body composition (11) Body weight (122) Blood biochemistry (83) Bariatric surgery (12) Bioinformatics (105) c-Fos activation (19) Clinical trial (2) Conditioned taste aversion test (1) Drug discovery (25) Drug distribution (11) Energy expenditure monitoring (4) Echocardiography (ECG) (3) Flow cytometry (1) Gut biopsy (6) Glomerular filtration rate (GFR) (8) Gastric emptying (3) Gut morphometry (12) Glucose-stimulated insulin secretion (GSIS) (1) Histopathology score (79) Heart morphometry (5) Intraperitoneal glucose tolerance test (IPGTT) (7) Image analysis (149) Immunohistochemistry (IHC) (143) In situ hybridization (ISH) (14) Insulin tolerance test (ITT) (2) Kidney biopsy (2) Kidney morphometry (24) Lung functional test (5) Light sheet fluorescence microscopy (LSFM) (59) Liver biopsy (67) Liver morphometry (64) Lung biochemistry (4) Laser-capture microdissection (LCM) (9) Magnetic resonance imaging (MRI) (2) Microbiomics (5) Micro-computed tomography (micro-CT) (1) Neurobehavior (6) Next-generation sequencing (49) Nephrectomy (14) Oral glucose tolerance test (OGTT) (20) Pancreatectomy (1) Peptide chemistry (14) Pharmacokinetics (9) Proteomics (1) qPCR (1) Real-time food intake/activity analysis (32) Receptor binding (3) Roux-en-Y gastric bypass (RYGB) (8) RNA sequencing (84) Single-cell RNA sequencing (3) Single-nucleus RNA sequencing (6) siRNA (1) StreaMLine (1) Surgery (12) Spirometry (5) Stereology (29) Stereotaxic injection (2) Ultrasound imaging (1) Urine biochemistry (12) Vasculature (2) Vertical sleeve gastrectomy (1) Western Blotting (1) Whole-body plethysmography (4) Whole-brain in situ hybridization (4) Species (218) Hamster (1) Human (30) Mouse (176) Minipig (2) Non-human primate (3) Pig (3) Rat (34) Show (28) Cancel Sort result Default sorting By title: alphabetical By title: reverse By date: oldest first By date: newest first Reset all × 5/6 nephrectomy (Nx) rat × DIO mouse × Renin–angiotensin system × 28 resource library items found PosterEffect of lisinopril on glomerular and tubular injury in a surgical rat model of progressive chronic kidney disease and kidney failure PosterEffect of lisinopril on glomerular and tubular injury in a surgical rat model of progressive chronic kidney disease and kidney failure PosterDistinct metabolic effects of semaglutide and resmetirom at thermoneutrality in diet-induced obese mice PosterStreaMLine – an innovative platform for peptide drug discovery PublicationAtlas of exercise-induced brain activation in mice PublicationTargeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment PublicationProtection against overfeeding-induced weight gain is preserved in obesity but does not require FGF21 or MC4R PublicationTAAR1 Agonists Improve Glycemic Control, Reduce Body Weight and Modulate Neurocircuits Governing Energy Balance and Feeding PublicationGLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity PosterNephroprotective effects of semaglutide in a mouse model of hypertension-accelerated diabetic kidney disease PosterNephroprotective effects of standard of care in a state-of-the-art mouse model of hypertension-accelerated diabetic kidney disease PublicationNephroprotective effects of semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease PublicationLipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect PublicationPeptide-YY3-36/glucagon-like peptide-1 combination treatment of obese-diabetic mice improves insulin sensitivity associated with recovered pancreatic ß-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries PublicationCharacterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice PublicationChronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism PublicationA genetic map of the mouse dorsal vagal complex and its role in obesity PublicationIdentification and metabolic profiling of a novel human gut-derived LEAP2 fragment PublicationAn optimized mouse brain atlas for automated mapping and quantification of neuronal activity using iDISCO+ and light sheet fluorescence microscopy PublicationResolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis PublicationMetabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice PublicationRhoA in tyrosine hydroxylase neurons regulates food intake and body weight via altered sensitivity to peripheral hormones PublicationAnimal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development PublicationThe role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach Load More For further information Contact us Gubra Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650